HRP20120361T1 - DERIVATI PIRAZOLO[3,4-b]PIRIDINA KAO INHIBITORI FOSFODIESTERAZE - Google Patents
DERIVATI PIRAZOLO[3,4-b]PIRIDINA KAO INHIBITORI FOSFODIESTERAZE Download PDFInfo
- Publication number
- HRP20120361T1 HRP20120361T1 HRP20120361AT HRP20120361T HRP20120361T1 HR P20120361 T1 HRP20120361 T1 HR P20120361T1 HR P20120361A T HRP20120361A T HR P20120361AT HR P20120361 T HRP20120361 T HR P20120361T HR P20120361 T1 HRP20120361 T1 HR P20120361T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- pyrazolo
- oxa
- pyridin
- ethyl
- Prior art date
Links
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 title 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 title 1
- 150000005230 pyrazolo[3,4-b]pyridines Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 546
- 125000000217 alkyl group Chemical group 0.000 claims abstract 39
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract 25
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 25
- 239000001257 hydrogen Substances 0.000 claims abstract 25
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims abstract 25
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 23
- 125000003118 aryl group Chemical group 0.000 claims abstract 22
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 20
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims abstract 16
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract 15
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 14
- 125000000304 alkynyl group Chemical group 0.000 claims abstract 14
- -1 hydroxy, carboxy Chemical group 0.000 claims abstract 10
- 150000003839 salts Chemical class 0.000 claims abstract 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims 29
- 238000006243 chemical reaction Methods 0.000 claims 22
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 17
- 238000002360 preparation method Methods 0.000 claims 14
- 125000004938 5-pyridyl group Chemical group N1=CC=CC(=C1)* 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 12
- 125000005843 halogen group Chemical group 0.000 claims 11
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 claims 10
- 230000003301 hydrolyzing effect Effects 0.000 claims 10
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 9
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 9
- 125000004432 carbon atom Chemical group C* 0.000 claims 8
- 238000010511 deprotection reaction Methods 0.000 claims 8
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 8
- 229920006395 saturated elastomer Polymers 0.000 claims 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 8
- 239000003112 inhibitor Substances 0.000 claims 7
- 125000006239 protecting group Chemical group 0.000 claims 6
- LFFBLXGLSVUNCU-UHFFFAOYSA-N 3-[4-(cyclohexylamino)-1-ethylpyrazolo[3,4-b]pyridin-5-yl]-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxylic acid Chemical compound N=1OC2(CCC(CC2)C(O)=O)CC=1C1=CN=C2N(CC)N=CC2=C1NC1CCCCC1 LFFBLXGLSVUNCU-UHFFFAOYSA-N 0.000 claims 4
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 4
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 4
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 238000007363 ring formation reaction Methods 0.000 claims 4
- 230000001629 suppression Effects 0.000 claims 4
- NZNMSOFKMUBTKW-UHFFFAOYSA-N Cyclohexanecarboxylic acid Natural products OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims 3
- TXWOGHSRPAYOML-UHFFFAOYSA-N cyclobutanecarboxylic acid Chemical compound OC(=O)C1CCC1 TXWOGHSRPAYOML-UHFFFAOYSA-N 0.000 claims 3
- VZFUCHSFHOYXIS-UHFFFAOYSA-N cycloheptane carboxylic acid Natural products OC(=O)C1CCCCCC1 VZFUCHSFHOYXIS-UHFFFAOYSA-N 0.000 claims 3
- 230000009977 dual effect Effects 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 230000001590 oxidative effect Effects 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 229910052698 phosphorus Inorganic materials 0.000 claims 3
- 239000011574 phosphorus Substances 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- YQHLBGCEOFVNRI-UHFFFAOYSA-N 3-[4-(cyclohexylamino)-1-ethylpyrazolo[3,4-b]pyridin-5-yl]-1-oxa-2-azaspiro[4.5]dec-2-en-8-ol Chemical compound N=1OC2(CCC(O)CC2)CC=1C1=CN=C2N(CC)N=CC2=C1NC1CCCCC1 YQHLBGCEOFVNRI-UHFFFAOYSA-N 0.000 claims 2
- NUKYPUAOHBNCPY-UHFFFAOYSA-N 4-aminopyridine Chemical compound NC1=CC=NC=C1 NUKYPUAOHBNCPY-UHFFFAOYSA-N 0.000 claims 2
- FVOWSQAKARXCSJ-UHFFFAOYSA-N 7-[4-(cyclohexylamino)-1-ethylpyrazolo[3,4-b]pyridin-5-yl]-5-oxa-6-azaspiro[3.4]oct-6-ene-2-carboxamide Chemical compound N=1OC2(CC(C2)C(N)=O)CC=1C1=CN=C2N(CC)N=CC2=C1NC1CCCCC1 FVOWSQAKARXCSJ-UHFFFAOYSA-N 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 201000009030 Carcinoma Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 102000001301 EGF receptor Human genes 0.000 claims 2
- 108060006698 EGF receptor Proteins 0.000 claims 2
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 208000015114 central nervous system disease Diseases 0.000 claims 2
- 206010009887 colitis Diseases 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000003401 eosinophilic granuloma Diseases 0.000 claims 2
- 229960004979 fampridine Drugs 0.000 claims 2
- 238000010438 heat treatment Methods 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 2
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 claims 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 230000035939 shock Effects 0.000 claims 2
- BUGOPWGPQGYYGR-UHFFFAOYSA-N thiane 1,1-dioxide Chemical compound O=S1(=O)CCCCC1 BUGOPWGPQGYYGR-UHFFFAOYSA-N 0.000 claims 2
- AXZYIQDVDKWBGB-UHFFFAOYSA-N 1-[3-[4-(cyclohexylamino)-1-ethylpyrazolo[3,4-b]pyridin-5-yl]-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]ethanone Chemical compound N=1OC2(CCN(CC2)C(C)=O)CC=1C1=CN=C2N(CC)N=CC2=C1NC1CCCCC1 AXZYIQDVDKWBGB-UHFFFAOYSA-N 0.000 claims 1
- CBJXSYDXPOWJOP-UHFFFAOYSA-N 1-ethyl-3-methyl-5-(1-oxa-2-azaspiro[4.4]non-2-en-3-yl)-n-(oxan-4-yl)pyrazolo[3,4-b]pyridin-4-amine Chemical compound N=1OC2(CCCC2)CC=1C1=CN=C2N(CC)N=C(C)C2=C1NC1CCOCC1 CBJXSYDXPOWJOP-UHFFFAOYSA-N 0.000 claims 1
- CWTRIHWOUYCONO-UHFFFAOYSA-N 1-ethyl-5-(1-oxa-2-azaspiro[4.4]non-2-en-3-yl)-n-pyrimidin-5-ylpyrazolo[3,4-b]pyridin-4-amine Chemical compound N=1OC2(CCCC2)CC=1C1=CN=C2N(CC)N=CC2=C1NC1=CN=CN=C1 CWTRIHWOUYCONO-UHFFFAOYSA-N 0.000 claims 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 claims 1
- PZFJUACXAVTYCR-UHFFFAOYSA-N 3-[1-ethyl-4-(oxan-4-ylamino)pyrazolo[3,4-b]pyridin-5-yl]-1-oxa-2-azaspiro[4.5]dec-2-en-8-ol Chemical compound N=1OC2(CCC(O)CC2)CC=1C1=CN=C2N(CC)N=CC2=C1NC1CCOCC1 PZFJUACXAVTYCR-UHFFFAOYSA-N 0.000 claims 1
- GNWLJMQPQWNRAW-UHFFFAOYSA-N 3-[4-(cyclohexylamino)-1-ethylpyrazolo[3,4-b]pyridin-5-yl]-1-oxa-2-azaspiro[4.5]dec-2-ene-8-carboxamide Chemical compound N=1OC2(CCC(CC2)C(N)=O)CC=1C1=CN=C2N(CC)N=CC2=C1NC1CCCCC1 GNWLJMQPQWNRAW-UHFFFAOYSA-N 0.000 claims 1
- NZSUFYLYXBAOOC-UHFFFAOYSA-N 3-[4-[(1,1-dioxothian-4-yl)amino]-1-ethyl-3-methylpyrazolo[3,4-b]pyridin-5-yl]-1-oxa-2-azaspiro[4.5]dec-2-en-8-ol Chemical compound N=1OC2(CCC(O)CC2)CC=1C1=CN=C2N(CC)N=C(C)C2=C1NC1CCS(=O)(=O)CC1 NZSUFYLYXBAOOC-UHFFFAOYSA-N 0.000 claims 1
- OFHRSRDKFXNNPG-UHFFFAOYSA-N 3-[[1-ethyl-3-methyl-5-(1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)pyrazolo[3,4-b]pyridin-4-yl]amino]cyclobutane-1-carboxylic acid Chemical compound N=1OC2(CCCCC2)CC=1C1=CN=C2N(CC)N=C(C)C2=C1NC1CC(C(O)=O)C1 OFHRSRDKFXNNPG-UHFFFAOYSA-N 0.000 claims 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 claims 1
- 102000019034 Chemokines Human genes 0.000 claims 1
- 108010012236 Chemokines Proteins 0.000 claims 1
- RENMDAKOXSCIGH-UHFFFAOYSA-N Chloroacetonitrile Chemical compound ClCC#N RENMDAKOXSCIGH-UHFFFAOYSA-N 0.000 claims 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N N-methylcyclohexylamine Natural products CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 claims 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 1
- JSSBOBLTLJDZPL-UHFFFAOYSA-N [7-[4-[(1,1-dioxothian-4-yl)amino]-1-ethylpyrazolo[3,4-b]pyridin-5-yl]-5-oxa-6-azaspiro[3.4]oct-6-en-2-yl]methanol Chemical compound N=1OC2(CC(CO)C2)CC=1C1=CN=C2N(CC)N=CC2=C1NC1CCS(=O)(=O)CC1 JSSBOBLTLJDZPL-UHFFFAOYSA-N 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 235000012501 ammonium carbonate Nutrition 0.000 claims 1
- 239000001099 ammonium carbonate Substances 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000003266 anti-allergic effect Effects 0.000 claims 1
- 239000000043 antiallergic agent Substances 0.000 claims 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 claims 1
- 239000000812 cholinergic antagonist Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- VEZUQRBDRNJBJY-UHFFFAOYSA-N cyclohexanone-oximeFRProcd Natural products ON=C1CCCCC1 VEZUQRBDRNJBJY-UHFFFAOYSA-N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 150000002367 halogens Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- NSVPFWRHCRYCLL-UHFFFAOYSA-N n-(1,1-dioxothian-4-yl)-1-ethyl-5-[8-(2h-tetrazol-5-yl)-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl]pyrazolo[3,4-b]pyridin-4-amine Chemical compound N=1OC2(CCC(CC2)C=2NN=NN=2)CC=1C1=CN=C2N(CC)N=CC2=C1NC1CCS(=O)(=O)CC1 NSVPFWRHCRYCLL-UHFFFAOYSA-N 0.000 claims 1
- CCHRNALXAWNKKL-UHFFFAOYSA-N n-cyclohexyl-5-(8-ethoxy-1-oxa-2-azaspiro[4.5]dec-2-en-3-yl)-1-ethylpyrazolo[3,4-b]pyridin-4-amine Chemical compound C1CC(OCC)CCC11ON=C(C=2C(=C3C=NN(CC)C3=NC=2)NC2CCCCC2)C1 CCHRNALXAWNKKL-UHFFFAOYSA-N 0.000 claims 1
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 1
- WQGWDDDVZFFDIG-UHFFFAOYSA-N pyrogallol Chemical compound OC1=CC=CC(O)=C1O WQGWDDDVZFFDIG-UHFFFAOYSA-N 0.000 claims 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Virology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Tropical Medicine & Parasitology (AREA)
- Otolaryngology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN550DE2007 | 2007-03-14 | ||
| PCT/IB2008/050943 WO2008111010A1 (en) | 2007-03-14 | 2008-03-14 | Pyrazolo (3, 4-b) pyridine derivatives as phosphodiesterase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120361T1 true HRP20120361T1 (hr) | 2012-05-31 |
Family
ID=39575541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20120361AT HRP20120361T1 (hr) | 2007-03-14 | 2012-04-23 | DERIVATI PIRAZOLO[3,4-b]PIRIDINA KAO INHIBITORI FOSFODIESTERAZE |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8420666B2 (ko) |
| EP (1) | EP2124944B1 (ko) |
| JP (1) | JP5671236B2 (ko) |
| KR (1) | KR101568884B1 (ko) |
| CN (2) | CN101801376A (ko) |
| AP (1) | AP2453A (ko) |
| AT (1) | ATE545417T1 (ko) |
| AU (1) | AU2008224541B2 (ko) |
| CA (1) | CA2680625C (ko) |
| CY (1) | CY1112805T1 (ko) |
| DK (1) | DK2124944T3 (ko) |
| EA (1) | EA018670B9 (ko) |
| ES (1) | ES2382715T3 (ko) |
| HK (1) | HK1138758A1 (ko) |
| HR (1) | HRP20120361T1 (ko) |
| MX (1) | MX2009009793A (ko) |
| NZ (1) | NZ579645A (ko) |
| PL (1) | PL2124944T3 (ko) |
| PT (1) | PT2124944E (ko) |
| SI (1) | SI2124944T1 (ko) |
| WO (1) | WO2008111010A1 (ko) |
| ZA (1) | ZA200906418B (ko) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007031838A1 (en) * | 2005-09-16 | 2007-03-22 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
| JP2009529047A (ja) * | 2006-03-07 | 2009-08-13 | アレイ バイオファーマ、インコーポレイテッド | ヘテロ二環系ピラゾール化合物およびその使用 |
| CA2655128A1 (en) * | 2006-06-08 | 2007-12-21 | Array Biopharma Inc. | Quinoline compounds and methods of use |
| WO2008019968A1 (en) * | 2006-08-16 | 2008-02-21 | F. Hoffmann-La Roche Ag | Non-nucleoside reverse transcriptase inhibitors |
| AU2009306026A1 (en) * | 2008-09-19 | 2010-04-29 | Ranbaxy Laboratories Limited | Phosphodiestarase inhibitors |
| CN102834102B (zh) | 2009-12-08 | 2015-01-14 | 范德比尔特大学 | 用于静脉采集和自体移植的改进的方法和组合物 |
| US10034861B2 (en) * | 2016-07-04 | 2018-07-31 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| US10246462B2 (en) | 2016-09-09 | 2019-04-02 | Flx Bio, Inc. | Chemokine receptor modulators and uses thereof |
| JOP20190126A1 (ar) | 2016-12-22 | 2019-05-28 | H Lundbeck As | بيرازولو [3، 4-b] بيريدينات وإيميدازو [1، 5-b] بيريدازينات على هيئة مثبطات PDE1 |
| EA037544B1 (ru) * | 2017-04-04 | 2021-04-12 | Х. Лундбекк А/С | ПРИМЕНЕНИЕ 1H-ПИРАЗОЛО[4,3-b]ПИРИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ PDE1 |
| CN111465410B (zh) * | 2017-12-14 | 2022-10-25 | H.隆德贝克有限公司 | 包括施用1h-吡唑并[4,3-b]吡啶的组合治疗 |
| AR113926A1 (es) | 2017-12-14 | 2020-07-01 | H Lundbeck As | Derivados de 1h-pirazolo[4,3-b]piridinas |
| US10766893B2 (en) | 2017-12-20 | 2020-09-08 | H. Lundbeck A/S | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors |
| TW201927784A (zh) | 2017-12-20 | 2019-07-16 | 丹麥商Ｈ 朗德貝克公司 | 作為pde1抑制劑之大環 |
| WO2019121840A1 (en) | 2017-12-20 | 2019-06-27 | H. Lundbeck A/S | Pyrazolo[3,4-b]pyridines and imidazo[1,5-b]pyridazines as pde1 inhibitors |
| CN113200997B (zh) * | 2021-05-07 | 2023-10-03 | 上海合全医药有限公司 | 2,5-二氧杂-8-氮杂螺[3.5]壬烷及其盐的合成方法 |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1047518A (en) | 1963-06-11 | 1966-11-02 | Glaxo Lab Ltd | 17ª-monoesters of 11,17,21-trihydroxy steroid compounds |
| NL128816C (ko) | 1965-04-22 | |||
| GB1158492A (en) | 1966-02-09 | 1969-07-16 | Boots Pure Drug Co Ltd | Improvements in Acylated Steroids |
| GB1200886A (en) | 1966-09-23 | 1970-08-05 | Allen & Hanburys Ltd | Phenylaminoethanol derivatives |
| US3937838A (en) | 1966-10-19 | 1976-02-10 | Aktiebolaget Draco | Orally active bronchospasmolytic compounds and their preparation |
| US3639434A (en) | 1967-02-02 | 1972-02-01 | Boots Pure Drug Co Ltd | 17-acyloxysteroids and their manufacture |
| US3780177A (en) | 1967-06-16 | 1973-12-18 | Warner Lambert Co | 17-butyrate,21-ester derivatives of 6alpha,9alpha-difluoroprednisolone,compositions and use |
| CH540244A (de) | 1967-11-17 | 1973-08-15 | Ciba Geigy Ag | Verfahren zur Herstellung neuer Halogenpregnadiene |
| GB1253831A (en) | 1968-01-19 | 1971-11-17 | Glaxo Lab Ltd | 9alpha,21-DIHALOPREGNANE COMPOUNDS |
| US3700681A (en) | 1971-02-16 | 1972-10-24 | Pfizer | 2-hydroxymethyl-3-hydroxy-6-(1-hydroxy-2-aminoethyl)pyridines |
| US3947478A (en) | 1972-01-12 | 1976-03-30 | Akzona Incorporated | Alkylated 3,20-diketo-Δ4 -steroids of the pregnane series |
| US3994974A (en) | 1972-02-05 | 1976-11-30 | Yamanouchi Pharmaceutical Co., Ltd. | α-Aminomethylbenzyl alcohol derivatives |
| SE378110B (ko) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| SE378109B (ko) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| US3992534A (en) | 1972-05-19 | 1976-11-16 | Ab Bofors | Compositions and method of treating with component B of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steriods |
| US4098804A (en) | 1973-05-30 | 1978-07-04 | Jouveinal S.A. | Esters of 21-thiol prednisone and prednisolone |
| FR2231374B1 (ko) | 1973-05-30 | 1976-10-22 | Jouveinal Sa | |
| US4011258A (en) | 1973-06-21 | 1977-03-08 | Aktiebolaget Draco | Orally active bronchospasmolytic compounds |
| ZA744259B (en) | 1973-08-17 | 1975-06-25 | American Cyanamid Co | Topical steroid |
| US3980778A (en) | 1973-10-25 | 1976-09-14 | The Upjohn Company | Anti-inflammatory steroid |
| NL7502252A (nl) | 1974-02-27 | 1975-08-29 | Pierrel Spa | Werkwijze voor het bereiden van een geneesmid- del met anti-inflammatoire werking, gevormd ge- neesmiddel verkregen volgens deze werkwijze alsmede werkwijze voor het bereiden van in het geneesmiddel gebruikte nieuwe steroiden. |
| DE2655570A1 (de) | 1975-12-12 | 1977-06-16 | Ciba Geigy Ag | Neue polyhalogensteroide und verfahren zu ihrer herstellung |
| US4076708A (en) | 1976-12-22 | 1978-02-28 | Schering Corporation | Process for the preparation of 7α-halogeno-3-oxo-4-dehydro steroids and novel 7α-halogeno derivatives produced thereby |
| US4124707A (en) | 1976-12-22 | 1978-11-07 | Schering Corporation | 7α-Halogeno-3,20-dioxo-1,4-pregnadienes, methods for their manufacture, their use as anti-inflammatory agents, and pharmaceutical formulations useful therefor |
| US4081541A (en) | 1976-12-28 | 1978-03-28 | Rorer Italiana S.P.A. | Steroid derivatives |
| DE2735110A1 (de) | 1977-08-04 | 1979-02-15 | Hoechst Ag | Corticoid-17-alkylcarbonate und verfahren zu ihrer herstellung |
| JPS6040439B2 (ja) | 1978-03-29 | 1985-09-11 | 大正製薬株式会社 | ヒドロコルチゾン誘導体 |
| ZA81976B (en) | 1980-02-15 | 1982-07-28 | Glaxo Group Ltd | Androstane carbothioates |
| ATE7689T1 (de) | 1980-07-09 | 1984-06-15 | Aktiebolaget Draco | 1-(dihydroxyphenyl)-2-amino-aethanol-derivate, verfahren und mittel zu ihrer herstellung sowie diese derivate enthaltende mittel. |
| US4298604B1 (en) | 1980-10-06 | 1998-12-22 | Schering Corp | Clotrimazole-betamethasone dipropionate combination |
| ATE8790T1 (de) | 1981-02-02 | 1984-08-15 | Schering Corporation | Aromatische heterocyclische steroidester, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen, die sie enthalten. |
| DE3133081A1 (de) | 1981-08-18 | 1983-03-10 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Neue 6(alpha)-methylprednisolon-derivate, ihre herstellung und verwendung |
| US4472392A (en) | 1983-01-21 | 1984-09-18 | The Upjohn Company | Sulfonate containing ester prodrugs of corticosteroids |
| ZW6584A1 (en) | 1983-04-18 | 1985-04-17 | Glaxo Group Ltd | Phenethanolamine derivatives |
| CA1240708A (en) | 1983-11-15 | 1988-08-16 | Johannes K. Minderhoud | Process for the preparation of hydrocarbons |
| CA1261835A (en) | 1984-08-20 | 1989-09-26 | Masaaki Toda | (fused) benz(thio)amides |
| GB8425104D0 (en) * | 1984-10-04 | 1984-11-07 | Ici America Inc | Amide derivatives |
| GB8607294D0 (en) | 1985-04-17 | 1986-04-30 | Ici America Inc | Heterocyclic amide derivatives |
| US4826868A (en) | 1986-05-29 | 1989-05-02 | Ortho Pharmaceutical Corporation | 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use |
| US4873259A (en) | 1987-06-10 | 1989-10-10 | Abbott Laboratories | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds |
| CA1326662C (en) | 1988-03-09 | 1994-02-01 | Yutaka Mizushima | 11.beta.,17.,21-trihydroxy-1,4-pregnadiene-3,20-dione 21-[(e,e)-3,7,11-trimethyl-2,6,10-dodecatrienoate] |
| US5278156A (en) | 1988-03-09 | 1994-01-11 | Kuraray Co., Ltd. | 11-beta, 17-alpha, 21-trihydroxy-1, 4-pregnadiene-3, 20 21-[(E-E)-3,7, 11-trimethyl-2,6,10-dodecatrienoate] |
| NZ234883A (en) | 1989-08-22 | 1995-01-27 | Merck Frosst Canada Inc | Quinolin-2-ylmethoxy indole derivatives, preparation and pharmaceutical compositions thereof |
| GR1001529B (el) | 1990-09-07 | 1994-03-31 | Elmuquimica Farm Sl | Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης. |
| IL99437A (en) | 1990-09-10 | 1995-05-29 | Schering Corp | Mumtazone Foroat Monohydrate, its preparation method and medicinal preparations |
| US5565473A (en) | 1990-10-12 | 1996-10-15 | Merck Frosst Canada, Inc. | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists |
| US6127353A (en) | 1991-09-06 | 2000-10-03 | Schering Corporation | Mometasone furoate monohydrate, process for making same and pharmaceutical compositions |
| US5254541A (en) | 1991-11-15 | 1993-10-19 | Merck Frosst Canada, Inc. | (Quinolin-2-ylmethoxy)indole/cyclodextrin complex |
| EP0542355A1 (en) | 1991-11-15 | 1993-05-19 | Merck Frosst Canada Inc. | Amorphous (Quinolin-2-ylmethoxy)indoles as leukotriene antagonists |
| US5837699A (en) | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| DZ1966A1 (fr) | 1995-02-06 | 2002-10-15 | Astra Ab | Combinaison pharmaceutique nouvelle. |
| CA2258728C (en) | 1996-06-19 | 2011-09-27 | Rhone Poulenc Rorer Limited | Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase |
| TR199802685T2 (xx) | 1996-06-25 | 1999-03-22 | Pfizer Inc | �kameli/katk�l� indazol t�revleri |
| US5976573A (en) | 1996-07-03 | 1999-11-02 | Rorer Pharmaceutical Products Inc. | Aqueous-based pharmaceutical composition |
| IL128642A0 (en) | 1996-09-04 | 2000-01-31 | Pfizer | Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf) |
| ZA985247B (en) | 1997-06-19 | 1999-12-17 | Du Pont Merck Pharma | Guanidine mimics as factor Xa inhibitors. |
| US6339099B1 (en) | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
| CN1138760C (zh) * | 1997-10-06 | 2004-02-18 | 惠氏控股公司 | 作为基质金属蛋白酶和tace抑制剂的邻亚磺酰氨基二环杂芳基异羟肟酸的制备和用途 |
| HUP0100330A3 (en) | 1997-11-04 | 2002-03-28 | Pfizer Prod Inc | Therapeutically active compounds based on indazole bioisostere replacement of catechol in pde4 inhibitors, compositions containing them and their use |
| SK6252000A3 (en) | 1997-11-04 | 2001-11-06 | Pfizer Prod Inc | Indazole bioisostere replacement of catechol in therapeutically active compounds |
| JP2000198734A (ja) | 1998-12-30 | 2000-07-18 | Pfizer Inc | 胃運動性減弱および関連疾患の治療のための運動性増強薬 |
| ATE241621T1 (de) | 1999-04-02 | 2003-06-15 | Bristol Myers Squibb Pharma Co | Arylsulfonyle als faktor xa inhibitoren |
| US20030176421A1 (en) | 1999-12-30 | 2003-09-18 | Watson John W. | Prokinetic agents for treating gastric hypomotility and related disorders |
| DE10050994A1 (de) | 2000-10-14 | 2002-04-18 | Boehringer Ingelheim Pharma | Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung |
| DE10050995A1 (de) | 2000-10-14 | 2002-04-18 | Boehringer Ingelheim Pharma | Neue Anticholinergika, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel |
| EP1345935A2 (en) | 2000-12-21 | 2003-09-24 | Warner-Lambert Company LLC | Piperidine derivatives as subtype selective n-methyl-d-aspartate antagonists |
| ATE327232T1 (de) | 2000-12-22 | 2006-06-15 | Wyeth Corp | Heterozyklylalkylindole oder -azaindole als 5- hydroxytryptamine-6 liganden |
| DE60129746T2 (de) | 2000-12-22 | 2008-04-30 | Wyeth | Hetorocyclindazole und -azaindazole verbindungen als 5-hydroxytryptamine-6 liganden |
| MXPA02002749A (es) | 2001-03-27 | 2002-10-28 | Warner Lambert Co | Derivados de ciclohexilamina como antagonistas del subtipo selectivo del n-metil-d-aspartato. |
| WO2002088079A2 (en) * | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
| TW200302225A (en) | 2001-12-04 | 2003-08-01 | Bristol Myers Squibb Co | Substituted amino methyl factor Xa inhibitors |
| IL164209A0 (en) | 2002-05-31 | 2005-12-18 | Eisai Co Ltd | Pyrazole derivatives and pharmaceutical compositions containing the same |
| GB0230045D0 (en) * | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| US7262200B2 (en) | 2002-10-25 | 2007-08-28 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| IS7839A (is) * | 2002-11-22 | 2004-05-23 | Merck Frosst Canada Ltd. | 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar |
| MXPA05009722A (es) | 2003-03-10 | 2006-03-09 | Schering Corp | Inhibidores heterociclicos de cinasa: metodos de uso y sintesis. |
| DE10318611A1 (de) * | 2003-04-24 | 2004-11-11 | Elbion Ag | 4-, 6- oder 7-Hydroxyindole mit N-Oxidgruppen und deren Verwendung als Therapeutika |
| KR101415503B1 (ko) | 2003-07-17 | 2014-07-04 | 플렉시콘, 인코퍼레이티드 | Ｐｐａｒ 활성 화합물 |
| CA2537185A1 (en) * | 2003-08-29 | 2005-03-10 | Ranbaxy Laboratories Limited | Inhibitors of phosphodiesterase type-iv |
| RS20060391A (en) | 2003-12-22 | 2008-11-28 | Memory Pharmaceuticals Corporation, | Indoles, 1h-indazoles, 1,2-benzisoxazoles, and 1,2- benzisothiazoles, and preparation and uses thereof |
| WO2006001894A1 (en) | 2004-04-22 | 2006-01-05 | Memory Pharmaceutical Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
| ES2319797T3 (es) | 2004-07-05 | 2009-05-12 | Astellas Pharma Inc. | Derivados de pirazolopiridina. |
| WO2006016237A2 (en) | 2004-08-04 | 2006-02-16 | Ranbaxy Laboratories Limited | Heterocyclic derivatives as anti-inflammatory agents |
| WO2006021848A1 (en) | 2004-08-27 | 2006-03-02 | Ranbaxy Laboratories Limited | Anti-inflammatory agents |
| US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
| MX2007006103A (es) | 2004-11-22 | 2007-07-20 | Vertex Pharma | Pirrolopirazinas y pirazolopirazinas de utilidad como inhibidores de proteinquinasas. |
| US20090131430A1 (en) | 2004-11-23 | 2009-05-21 | Palle Venkata P | Pyrido'2,3-dipyrimidines as anti-inflammatory agents |
| JP2008521829A (ja) | 2004-11-30 | 2008-06-26 | プレキシコン，インコーポレーテッド | Ｐｐａｒ活性化合物 |
| JP2008521831A (ja) | 2004-11-30 | 2008-06-26 | プレキシコン，インコーポレーテッド | Ｐｐａｒ活性化合物 |
| EP1846403A1 (en) | 2005-02-02 | 2007-10-24 | Ranbaxy Laboratories Limited | Azabicyclo derivatives as anti-inflammatory agents |
| CA2599662A1 (en) | 2005-03-01 | 2006-09-08 | Pfizer Limited | Use of pde7 inhibitors for the treatment of neuropathic pain |
| WO2006117657A1 (en) | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Triazolone derivatives as anti-inflammatory agents |
| US20100022571A1 (en) | 2005-09-16 | 2010-01-28 | Palle Venkata P | Substituted pyrazolo [3,4-b]pyridines as phosphodiesterase inhibitors |
| JP2009510044A (ja) * | 2005-09-29 | 2009-03-12 | グラクソ グループ リミテッド | ピラゾロ［３，４−ｂ］ピリジン化合物及びそのＰＤＥ４阻害薬としての使用 |
| US20120004201A1 (en) * | 2008-09-19 | 2012-01-05 | Sonali Rudra | Phosphodiestarase inhibitors |
-
2008
- 2008-03-14 CA CA2680625A patent/CA2680625C/en not_active Expired - Fee Related
- 2008-03-14 SI SI200830590T patent/SI2124944T1/sl unknown
- 2008-03-14 AT AT08737621T patent/ATE545417T1/de active
- 2008-03-14 KR KR1020097021120A patent/KR101568884B1/ko not_active IP Right Cessation
- 2008-03-14 US US12/531,043 patent/US8420666B2/en not_active Expired - Fee Related
- 2008-03-14 CN CN200880014410A patent/CN101801376A/zh active Pending
- 2008-03-14 CN CN201310379773.0A patent/CN103497185A/zh active Pending
- 2008-03-14 AU AU2008224541A patent/AU2008224541B2/en not_active Ceased
- 2008-03-14 AP AP2009004977A patent/AP2453A/xx active
- 2008-03-14 EA EA200970852A patent/EA018670B9/ru not_active IP Right Cessation
- 2008-03-14 EP EP08737621A patent/EP2124944B1/en not_active Not-in-force
- 2008-03-14 WO PCT/IB2008/050943 patent/WO2008111010A1/en active Application Filing
- 2008-03-14 JP JP2009553263A patent/JP5671236B2/ja not_active Expired - Fee Related
- 2008-03-14 ES ES08737621T patent/ES2382715T3/es active Active
- 2008-03-14 DK DK08737621.6T patent/DK2124944T3/da active
- 2008-03-14 NZ NZ579645A patent/NZ579645A/en not_active IP Right Cessation
- 2008-03-14 PL PL08737621T patent/PL2124944T3/pl unknown
- 2008-03-14 MX MX2009009793A patent/MX2009009793A/es active IP Right Grant
- 2008-03-14 PT PT08737621T patent/PT2124944E/pt unknown
-
2009
- 2009-09-15 ZA ZA200906418A patent/ZA200906418B/xx unknown
-
2010
- 2010-05-11 HK HK10104603.9A patent/HK1138758A1/xx not_active IP Right Cessation
-
2012
- 2012-04-23 HR HRP20120361AT patent/HRP20120361T1/hr unknown
- 2012-04-26 CY CY20121100403T patent/CY1112805T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2124944E (pt) | 2012-05-17 |
| EA200970852A1 (ru) | 2010-04-30 |
| ZA200906418B (en) | 2010-05-26 |
| WO2008111010A1 (en) | 2008-09-18 |
| CA2680625C (en) | 2016-02-23 |
| AU2008224541B2 (en) | 2013-08-22 |
| CN101801376A (zh) | 2010-08-11 |
| EP2124944A1 (en) | 2009-12-02 |
| HK1138758A1 (en) | 2010-09-03 |
| AU2008224541A1 (en) | 2008-09-18 |
| EA018670B9 (ru) | 2014-01-30 |
| CA2680625A1 (en) | 2008-09-18 |
| MX2009009793A (es) | 2009-10-16 |
| EP2124944B1 (en) | 2012-02-15 |
| JP5671236B2 (ja) | 2015-02-18 |
| SI2124944T1 (sl) | 2012-05-31 |
| CY1112805T1 (el) | 2016-02-10 |
| AP2453A (en) | 2012-08-31 |
| CN103497185A (zh) | 2014-01-08 |
| AP2009004977A0 (en) | 2009-10-31 |
| DK2124944T3 (da) | 2012-04-23 |
| JP2010521451A (ja) | 2010-06-24 |
| EA018670B1 (ru) | 2013-09-30 |
| KR101568884B1 (ko) | 2015-11-12 |
| ATE545417T1 (de) | 2012-03-15 |
| ES2382715T3 (es) | 2012-06-12 |
| KR20090120505A (ko) | 2009-11-24 |
| NZ579645A (en) | 2012-01-12 |
| US8420666B2 (en) | 2013-04-16 |
| PL2124944T3 (pl) | 2012-08-31 |
| US20100292196A1 (en) | 2010-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120361T1 (hr) | DERIVATI PIRAZOLO[3,4-b]PIRIDINA KAO INHIBITORI FOSFODIESTERAZE | |
| JP2010521451A5 (ko) | ||
| EP1866310B1 (en) | 2,3-substituted fused pyrimidin-4(3h)-ones as vr1 antagonists | |
| ES2346674T3 (es) | Compuestos heteroaromaticos de quinolina y su uso como inhibidores de pde10. | |
| US7902373B2 (en) | Nicotinamide derivatives | |
| US6965030B2 (en) | 6-alkoxy-pyrido-pyridine | |
| JP5296526B2 (ja) | ピラゾロピリジン類およびこれらの類似体 | |
| KR101312736B1 (ko) | 피라졸로피리딘 유도체 | |
| AU2004315876B2 (en) | Pyrazolopyridines and analogs thereof | |
| KR20160135283A (ko) | 5-치환된 인다졸-3-카르복스아미드 및 이의 제조 및 용도 | |
| CA2778680A1 (en) | N-containing heteroaryl derivatives as jak3 kinase inhibitors | |
| CA2921880A1 (en) | Alkynyl alcohols and methods of use | |
| BR112020000029A2 (pt) | compostos e composições farmacêuticas dos mesmos para o tratamento de fibrose | |
| AU2007287319A1 (en) | Pyrimidone compounds as GSK-3 inhibitors | |
| KR20140026627A (ko) | 인다졸 | |
| WO2005105801A1 (en) | Pyrrolyl substituted pyrido[2,3-d]pyrimidin-7-ones and derivatives thereof as therapeutic agents | |
| AU2012286426A1 (en) | BTK inhibitors | |
| EP0378255A2 (en) | 2-Aminopyrimidinone derivatives | |
| WO2007077490A2 (en) | Bicyclic heteroaryl compounds as pde10 inhibitors | |
| DE60307462T2 (de) | 8-fluorimidazo(1,2-a)pyridin derivative als liganden für gaba rezeptoren | |
| JP2004531499A (ja) | Ｇａｂａ受容体用リガンドとしてのイミダゾ−ピリミジン誘導体 | |
| WO2002040019A1 (fr) | Derives benzimidazoles | |
| JP3463935B2 (ja) | 中枢神経系障害の処置において有用な３−オキソ−ピリド（１，２−▲ａ▼）ベンズイミダゾール−４−カルボキシル及び４−オキソ−アゼピノ（１，２−▲ａ▼）ベンズイミダゾール−５−カルボキシル誘導体 | |
| AU2009212410A1 (en) | Dual pharmacophores - PDE4-muscarinic antagonistics | |
| AU2014201789B2 (en) | N-containing heteroaryl derivatives as JAK3 kinase inhibitors |